Mar 14,2023

SelectHealth brings Vida Health virtual health solutions to members managing chronic conditions

SelectHealth®, a nonprofit health plan serving more than one million members in Utah, Idaho, and Nevada, is pleased to announce a new relationship with virtual cardiometabolic care leader Vida Health effective March 2023. The relationship provides SelectHealth Medicare Advantage and Individual plan members with access to Vida’s virtual cardiometabolic solutions for chronic physical and mental health conditions. Eligible SelectHealth members can now tap Vida’s extensive resources for chronic conditions and associated mental health ailments, such as diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), depression and anxiety. Resources include licensed therapists, dietitians, diabetes educators and certified health coaches.

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
May 31,2023

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress

Akili, Inc. is presenting pivotal trial data on EndeavorRx® (AKL-T01) in adolescents with attention-deficit/hyperactivity disorder (ADHD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach on May 31, 2023, and at the Elevate Psych Congress in Las Vegas on June 2-3, 2023. The multi-center open-label study enrolled 162 adolescents ages 13-17 with inattentive or combined-type ADHD. After four weeks of treatment with EndeavorRx, trial participants saw significant improvements across a wide range of clinical outcomes, including in their attention and ADHD-related symptoms. EndeavorRx is currently authorized for use in 8-12 year olds with ADHD. Based on these new data, Akili has filed with FDA to expand its current EndeavorRx label to include 13-17 year olds.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 12,2023

Dexcom study shows diabetes’ impact on mental health

A Dexcom study shows that diabetes has a significant negative impact on mental health, according to 84% of respondents. Additionally, 91% believe that technology enables a balanced lifestyle while managing diabetes. Dexcom, a maker of continuous glucose monitor (CGM) technology, announced results ahead of the UK’s Diabetes Awareness Week. It included responses from 1,000 nationally representative UK respondents aged 16 years and up living with diabetes.

View Analyst & Ambassador Comments
Go to original news
Jun 07,2023 TOP STORY

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with ADHD

Akili, Inc. today released EndeavorOTC, a new immersive mobile video game treatment that is clinically proven to improve attention and focus, specifically in adults with ADHD. EndeavorOTC is built on the same technology as Akili’s EndeavorRx, the world’s first and only FDA-authorized video game treatment now being prescribed for children 8-12 years old with ADHD. EndeavorOTC is now available without a prescription for adults 18 years and older nationwide. The release of EndeavorOTC provides immediate access to this clinically-proven non-drug option for those seeking new safe and effective solutions to their treatment needs. The first generation of EndeavorOTC is available now in the Apple App Store for adults 18 and older with ADHD. Akili will actively involve adults using EndeavorOTC in the ongoing development of the product, gathering feedback that will help shape future generations of the game.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Q&A: Nox Health on its $3.9M bid for Pear Therapeutics' assets

Nox Health, a tech-enabled sleep health company, made the highest bid of $3.9 million for the assets of Pear Therapeutics' Somryst at a recent bankruptcy auction. Somryst is an FDA-cleared prescription digital therapeutic that utilizes cognitive behavioral therapy for insomnia. Nox Health aims to integrate Somryst into its comprehensive sleep management program, offering proven outcomes for patients with chronic insomnia and complementing its existing offerings in sleep health. The company plans to make Somryst accessible to physicians and patients while continuing to invest in its improvement.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 24,2023

Koa Health Partners with International SOS to enable global access to mental healthcare across the continuum

Koa Health has partnered with International SOS to expand global access to mental healthcare throughout the continuum. Through their partnership, Koa Health's clinically validated mental wellbeing app, Koa Foundations, will integrate into International SOS' mental health ecosystem, supporting employee mental health. Koa Foundations offers evidence-based interventions and activities, addressing common challenges such as stress and burnout. This collaboration aims to enhance mental resilience, reduce risks, and promote positive outcomes for workers worldwide.

COLLABORATION PARTNERSHIP

#institution

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 12,2023

Rocket VR Health announces corporate re-branding and changes name to "Novobeing"

Virtual reality company, Rocket VR Health, has rebranded to Novobeing, marking a shift towards non-clinical wellness applications to augment its evidence-based VR digital therapeutics. Novobeing has developed innovative digital therapeutics for reducing distress and anxiety in patients undergoing long hospital stays and is currently conducting three clinical trials to study and improve the efficacy of its virtual reality digital therapeutics.

#virtual reality

#cbt

View Analyst & Ambassador Comments
Go to original news
May 03,2023

HelloBetter received FDA Breakthrough Device Designation for Digital Therapeutic to treat Panic Disorder

HelloBetter, one of the world’s leading providers in developing and commercializing software-based medicines called prescription digital therapeutics (PDTx), has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its DTx HelloBetter Panic. Securing Breakthrough Device Designation represents the next step in HelloBetter’s long term strategy to access the US market, after the 2022 launch of the US-brand HelloGina.

REGULATORY FDA

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 23,2023

Clinical Trial of Arcade Therapeutics' Flagship Therapeutic Mobile Game, StarStarter Rx, Shows Robust Reductions in Social Anxiety in Adults

Arcade Therapeutics (formerly Wise Therapeutics) has announced topline results of their StarStarter Rx Pilot Study, evaluating the efficacy and safety of their flagship digital therapeutic in adults aged 22-65 with Social Anxiety Disorder (SAD). The clinical trial showed that StarStarter Rx reduced social anxiety symptoms in over 90% of patients, with a 33% average decrease, which was statistically significantly greater than that of the gold-standard placebo control. 68% of patients showed clinically meaningful reductions in their anxiety severity level, with 38% showing reductions to sub-clinical cutoffs. Arcade plans to pursue FDA submission for StarStarter Rx, which applies the cognitive training technique Attention Bias Modification through an engaging mobile game format

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Digital therapeutics startup Mindset Health scores $12M in Series A funding

Australian digital therapeutics startup Mindset Health has raised $12m in a series A funding round to develop and launch new hypnosis-based DTx apps. The round was led by King River Capital and included participation from Tenmile, Yard Ventures, WordPress founder Matt Mullenweg, and Linktree founders Anthony Zaccaria and Nick Humphreys. Mindset Health's existing range of DTx apps address health conditions such as irritable bowel syndrome, menopause and smoking cessation. The company plans to use the new funds to develop apps for anxiety and depression, sleep, and chronic pain, and to strengthen its existing apps with additional features and personalisation

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH